Aug 12, 2020
Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck
Jun 22, 2020
Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19
Jun 09, 2020
Global Neoantigen Cancer Vaccines Market to Exhibit a CAGR of ~35% During 2020-2025
May 07, 2020
Therapeutic Vaccines Industry Analysis and Forecast 2015-2025 (COVID-19 Adjusted)
Apr 23, 2020
Neoantigen-based Personalized Cancer Therapeutic Vaccines Competitive Landscape and Market Forecast 2035
Feb 28, 2020
John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanoma
Feb 28, 2020
John Theurer Cancer Center Launches Clinical Trial of Personalized Cancer Vaccine Using New Gene-Based Technology for High-Risk Melanoma
Feb 27, 2020
$200B+ Cancer Immunotherapy Market Opportunity Insights, 2026 - Cancer Vaccines, Monoclonal Antibodies, Trials of T-Cell Therapies, Pipeline Overview, Competitive Landscape, and More
Feb 20, 2020
Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer
Feb 10, 2020
Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026
Feb 06, 2020
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Jan 14, 2020
The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030
Jan 08, 2020
Agenus Commences Phase 1 trial with AGEN1223
Nov 21, 2019
Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients
Nov 08, 2019
Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical's Phase 2 Clinical Trial to be Presented at SITC Annual Meeting
Nov 06, 2019
Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L, at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 06, 2019
Ervaxx Launches to Pioneer the Use of Dark Antigens(TM) for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies
Oct 23, 2019
Global Personalized Cancer Vaccine Market Report 2019: Clinical Trials & Future Outlook 2026 - Advancements in Genome Sequencing Techniques Delivering Better Personalized Cancer Vaccines
Oct 02, 2019
AIVITA Biomedical Announces Publication Concerning a Predictive Biomarker for Melanoma Patients Treated with the Company's Platform Immunotherapy
Sep 02, 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki